Skip to content

Sleep Timing and Insulin Resistance in Adolescents With Obesity

Investigating the Relationship Between Circadian Phase and Insulin Resistance in Obese Adolescents

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02585830
Enrollment
25
Registered
2015-10-23
Start date
2015-10-31
Completion date
2017-05-31
Last updated
2020-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Brief summary

This study examines the relationship between sleep timing and insulin resistance in adolescents with obesity. The investigators also aim to develop a physiologically-based mathematical model of adolescent sleep/wake and circadian interactions.

Interventions

None listed

Sponsors

University of Colorado, Denver
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
15 Years to 19 Years
Healthy volunteers
Yes

Inclusion criteria

* High school students between the ages of 15-19 * BMI \> 90th percentile * Tanner stage 2 or greater

Exclusion criteria

* Any medications that affect insulin resistance or sleep (e.g., metformin, hormonal contraception, stimulants, atypical antipsychotics) * Regular use of melatonin or sleep aids * A prior diagnosis of obstructive sleep apnea, diabetes (HbA1c \> 6.5), liver disease other than non-alcoholic fatty liver disease, pregnancy or breastfeeding * IQ \< 70 or severe mental illness that may impact sleep (e.g., schizophrenia, psychotic episodes) * Not enrolled in a traditional high school academic program (e.g., home school students) * Night shift employment * Travel across more than 2 time zones in the month prior to the study

Design outcomes

Primary

MeasureTime frameDescription
Insulin Sensitivity3 hoursAfter an overnight fast, participants completed an oral glucose tolerance test (OGTT) in the morning. Participants consumed a 75g dextrose drink and serum for glucose and insulin concentrations were collected at baseline and every 30 minutes for 3 hours. The homeostatic model assessment for insulin resistance (HOMA-IR) was calculated as \[fasting insulin (μU/ml) x fasting glucose (mmol/l)\] / 22.5); lower HOMA-IR indicates better insulin sensitivity. The Matsuda Index was calculated as √10,000 / \[\[fasting insulin (μU/ml) x fasting glucose (mmol/l)\] x \[mean OSTT insulin (μU/ml) x mean OSTT glucose (mmol/l)\]\]; high Matsuda Index indicates better insulin sensitivity.
Dim Light Melatonin Onset and Offset1 day\ 1mL saliva was collected at 30- to 60- minute intervals in dim light (\<5 lux in the angle of gaze, approximately the light level of candlelight or civil twilight) from approximately 5pm until noon the next day. Dim light melatonin onset (DLMOn) was defined as the linear interpolated clock time at which evening salivary melatonin concentrations increased and remained above a threshold of 3pg/mL. Melatonin offset (DLMOff) was the linear interpolated clock time at which salivary melatonin concentrations fell below this threshold. Later DLMOn and DLMOff are indicative of a later circadian rhythm.

Countries

United States

Participant flow

Participants by arm

ArmCount
Observation
Home and in-lab observation
25
Total25

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyWithdrawal by Subject3

Baseline characteristics

CharacteristicObservation
Age, Continuous16.48 years
STANDARD_DEVIATION 1.09
BMI97.04 percentile
STANDARD_DEVIATION 2.39
Ethnicity (NIH/OMB)
Hispanic or Latino
18 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
7 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
6 Participants
Race (NIH/OMB)
More than one race
6 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants
Race (NIH/OMB)
White
12 Participants
Region of Enrollment
United States
25 participants
Sex: Female, Male
Female
15 Participants
Sex: Female, Male
Male
10 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 25
other
Total, other adverse events
0 / 25
serious
Total, serious adverse events
0 / 25

Outcome results

Primary

Dim Light Melatonin Onset and Offset

\ 1mL saliva was collected at 30- to 60- minute intervals in dim light (\<5 lux in the angle of gaze, approximately the light level of candlelight or civil twilight) from approximately 5pm until noon the next day. Dim light melatonin onset (DLMOn) was defined as the linear interpolated clock time at which evening salivary melatonin concentrations increased and remained above a threshold of 3pg/mL. Melatonin offset (DLMOff) was the linear interpolated clock time at which salivary melatonin concentrations fell below this threshold. Later DLMOn and DLMOff are indicative of a later circadian rhythm.

Time frame: 1 day

ArmMeasureGroupValue (MEAN)Dispersion
ObservationDim Light Melatonin Onset and OffsetDim Light Melatonin Onset21.33 decimal hoursStandard Deviation 1.47
ObservationDim Light Melatonin Onset and OffsetDim Light Melatonin Offset8.32 decimal hoursStandard Deviation 1.09
Primary

Insulin Sensitivity

After an overnight fast, participants completed an oral glucose tolerance test (OGTT) in the morning. Participants consumed a 75g dextrose drink and serum for glucose and insulin concentrations were collected at baseline and every 30 minutes for 3 hours. The homeostatic model assessment for insulin resistance (HOMA-IR) was calculated as \[fasting insulin (μU/ml) x fasting glucose (mmol/l)\] / 22.5); lower HOMA-IR indicates better insulin sensitivity. The Matsuda Index was calculated as √10,000 / \[\[fasting insulin (μU/ml) x fasting glucose (mmol/l)\] x \[mean OSTT insulin (μU/ml) x mean OSTT glucose (mmol/l)\]\]; high Matsuda Index indicates better insulin sensitivity.

Time frame: 3 hours

Population: 1 participant with missing data

ArmMeasureGroupValue (MEAN)Dispersion
ObservationInsulin SensitivityHomeostatic Model Assessment (HOMA-IR)2.9 units on a scaleStandard Deviation 2.01
ObservationInsulin SensitivityMatsuda Index4.93 units on a scaleStandard Deviation 2.75

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026